LR-HEALTH-&-BEAUTY
15.10.2019 17:25:30 CEST | Business Wire | Press release
LR Health & Beauty is further expanding its Aloe vera product portfolio with its new product Aloe Vera Drinking Gel Immune Plus. The development and manufacturing of Aloe vera products has been one of the core competences of the global direct sales company for more than 17 years. True to the motto "More quality for your life", LR now presents Immune Plus as a premium product to support the immune system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005834/en/
The Aloe Vera Drinking Gels have been LR’s bestsellers since 2002. They offer support in different life situations and are available in various flavors. The special feature of Immune Plus is the synergetic interaction of the ingredients – 85% Aloe vera leaf gel with 8% honey, 6% ginger juice and lemon juice, enriched with vitamin C, zinc and selenium – which have a holistic strengthening effect on the immune system. “We are convinced that with our high-quality product innovation in the field of nutritional supplements, we are continuing the success story of our Aloe Vera Drinking Gels”, states Andreas Friesch, CEO of LR Health & Beauty.
All Aloe Vera Drinking Gels meet the strict internal quality standards and are also distinguished by the quality seal of the SGS INSTITUT FRESENIUS and the International Aloe Science Council (IASC). Regular inspections by the IASC ensure high Aloe vera quality – from cultivation to processing in Germany. Only high-quality Aloe vera gel is used for the products. LR obtains the gel from Mexico, where the plant is cultivated on nutrient-rich volcanic soil. Another seal of quality: SGS INSTITUT FRESENIUS regularly checks LR’s Aloe Vera Drinking Gels, makes blind purchases, checks the finished products and packaging and once a year inspects the production facilities. “Quality is our top priority. This is why, in addition to our own extensive laboratory tests, we also have our Drinking Gels inspected by renowned, independent institutes,” says Andreas Friesch.
With annual processing of around 12,000 tons of Aloe vera leaves, LR is one of the world’s largest manufacturers of Aloe vera products. In addition to the Aloe Vera Drinking Gel, the company’s Aloe vera expertise is also reflected in the brand LR ALOE VIA, which covers the areas of care, cleaning and regeneration.
LR Health & Beauty
The LR Group, headquartered in Ahlen (Germany), produces and markets various beauty and health products in 28 countries. These include care and decorative cosmetics, dietary supplements and perfumes. The processing of Aloe vera has been one of LR Health & Beauty's core competences for over 17 years. In Ahlen, the company has Europe's most modern Aloe vera production facility for Aloe Vera Drinking Gel. With 1,100 employees and thousands of registered sales partners and customers, LR is one of the leading direct sales companies in Europe.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005834/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients8.4.2026 08:15:00 CEST | Press release
This record closing is the largest raise ever achieved by a fully independent European fund dedicated to Biopharma, validating Jeito’s patient-driven investment strategy, its multidisciplinary, collaborative expertise spanning from science to commercialization of medicines, and value creationIn five years, Jeito Capital has tripled its assets under management to €1.6 billion, firmly establishing itself among the top-tier global Biopharma investorsJeito II will build on Jeito I’s proven and differentiated strategy, investing in the most promising clinical Biopharma companies which address unmet patient needs and severe diseases, accelerate breakthrough therapeutic innovation, and deliver transformative benefits for patientsThis fundraise represents significant momentum for European Biopharma, strengthening its financial firepower and expertise to develop the next generation of global champions Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, toda
Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 07:00:00 CEST | Press release
Hyaluronic acid product for knee osteoarthritis available in the EU and Switzerland from May 2026 Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of
Murata Begins Mass Production of Seven Automotive MLCCs with World-leading Capacitance for Their Rated Voltage and Size, Supporting Stable Operation of In-vehicle Systems and Greater Design Flexibility8.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of seven AEC-Q200-qualified multilayer ceramic capacitors (MLCCs) that achieve the world’s largest capacitance for a given rated voltage and size*, supporting stable operation of in-vehicle systems and greater design flexibility. Five parts in the GCM series are rated at 2.5-4 Vdc, targeting IC peripheral circuits in advanced driver assistance systems (ADAS) and autonomous driving (AD) applications. The remaining two MLCCs are rated at 25 Vdc for in-vehicle power line applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407486750/en/ [Murata Manufacturing Co., Ltd.] Seven automotive MLCCs In recent years, as ADAS and AD technologies advance, the number and performance level of systems installed in vehicles have continued to increase. As a result, demand for higher capacitance low-voltage MLCCs used around ICs has grown to e
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7.4.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The equity awards were granted on April 1, 2026 and consisted of options to purchase an aggregate of 117,445 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 55,875 shares. The options have an exercise price per share equal to $5.62, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted s
SLB OneSubsea and Subsea7 Sign Collaboration Agreement with PETRONAS Suriname7.4.2026 22:05:00 CEST | Press release
Partnership enables early engagement to co-develop cost-effective solutions and accelerate subsea development in Suriname Global energy technology company SLB (NYSE: SLB) today announced the signing of a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331210557/en/ SLB OneSubsea has signed a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea soluti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom